Related Experiment Video

Updated: Jun 10, 2026

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Microscopic polyangiitis: Clinical presentation

Peter M Villiger1, Loïc Guillevin

  • 1Department of Rheumatology, Clinical Immunology and Allergology, University Hospital and University of Bern, Switzerland.

Autoimmunity Reviews
|July 27, 2010
PubMed

Insights

Microscopic polyangiitis (MPA) is a pauci-immune small vessel vasculitis. Treatment depends on disease severity, using immunosuppressants like cyclophosphamide, rituximab, and glucocorticoids for remission and maintenance.

Area of Science:

  • Rheumatology
  • Immunology
  • Nephrology

Background:

  • Microscopic polyangiitis (MPA) is a pauci-immune small vessel vasculitis associated with Antineutrophil Cytoplasmic Antibodies (ANCA).
  • MPA typically affects the kidneys and lungs, significantly impacting patient prognosis.
  • It predominantly affects individuals over 50, with a higher prevalence in men.

Purpose of the Study:

  • To provide a comprehensive overview of Microscopic Polyangiitis (MPA).
  • To detail the diagnostic characteristics, epidemiology, and clinical manifestations of MPA.
  • To outline current treatment strategies based on disease severity and organ involvement.

Main Methods:

  • Review of histological findings characteristic of MPA (necrotizing small vessel vasculitis, pauci-immune).
  • Analysis of epidemiological data regarding MPA prevalence, age, and sex distribution.
  • Summary of treatment protocols, including induction and maintenance therapies for MPA.

Main Results:

  • MPA is characterized by pauci-immune necrotizing small vessel vasculitis.
  • Kidney and lung involvement are key prognostic factors.
  • Treatment strategies vary from glucocorticoids and cyclophosphamide for severe disease to methotrexate and biologics like rituximab.

Conclusions:

  • MPA requires tailored treatment based on the Five Factor Score (FFS) and organ involvement.
  • Induction therapy involves potent immunosuppression, while maintenance aims for long-term remission.
  • Emerging biologic therapies offer new avenues for MPA management.

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Related Concept Videos

Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such as Proteus,...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...